KX-826 users: 0.5% vs 0.9% vs foam Technology 8/3/2025
KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity If we lose hair because of our sensitivity to DHT, then why are we trying to reduce DHT when our sensitive androgen receptors are the culprit?
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
community Why are there no meaningful baseline blood tests for pyrilutamide (KX-826) like there are for finasteride?
Finasteride reduces DHT production, so blood tests can track hormonal changes. Pyrilutamide blocks androgen receptors without altering hormone levels, making blood tests less useful for detecting its effects.
community New angles to attack beyond DHT
Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.
community Kintor’s KX-826 Pyrilutamide!!
KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.
community KX-826 and RU58841: do topical anti-androgens work?
KX-826 and RU58841 are topical anti-androgens discussed for hair loss prevention, with KX-826 showing promise in trials and RU58841 having mixed anecdotal results. Users report combining these with treatments like minoxidil, finasteride, and dutasteride, with varying success and concerns about side effects.
Related Research
6 / 6 results
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
research Mechanism exploration of the combined use of minoxidil with natural compounds ginsenoside Rg3 and glycyrrhizic acid for enhancing androgenic alopecia therapy
In mouse studies, this research found that combining ginsenoside Rg3 and glycyrrhizic acid with minoxidil improved treatment outcomes for androgen alopecia by addressing both symptoms and root causes, notably activating the Wnt/β-catenin pathway and promoting hair follicle cell proliferation.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Molecular Mechanisms and Targeted Therapeutics in Androgenetic Alopecia: From Signaling Pathways to Regenerative Approaches
This review examines androgenetic alopecia, detailing its causes and current treatments, but reports no new clinical results; the authors emphasize understanding its complexity for personalized therapy development.
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.